Clinical trials: Diabetes Type 1
Type 1 Diabetes Mellitus
The International Diabetes Closed Loop (iDCL) Trial: Clinical Acceptance of the Artificial Pancreas
The objective of the study is to assess efficacy and safety of a closed loop system (t:slim X2 with Control-IQ Technology) in a large randomized controlled trial.
- Trial name
- DCLP3 (NCT03563313)
- Testing
- t:slim X2 with Control-IQ Technology & Dexcom G6 CGM, Sensor-augmented pump (SAP)
- Where
- 7 sites in United States
- Volunteers
- 168 people
- Sponsor
- University of Virginia
Diabetes, Diabetes Mellitus, Type 1
Comparison of Insulin Detemir and Insulin Aspart in 2 Separate Injections Twice Daily to Extemporaneous Mixing Injection Regimen Twice Daily - The Paediatric Mixing Trial
This trial is conducted in Europe. The aim of the trial is to compare two methods of injection in basal-bolus insulin regimen in children with type 1 diabetes with insulin detemir associated with insulin aspart given twice daily…
- Trial name
- MIXING (NCT00542620)
- Testing
- insulin detemir, insulin aspart
- Where
- France
- Volunteers
- 25 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes
Hybrid Closed-Loop Control With Smart Prandial Insulin Dosing in Type 1 Diabetes
The objective of this study is to evaluate the safety and feasibility of a smart bolus calculator that adjusts insulin dosing for meals according to real-time insulin sensitivity (SI) in adolescents with type 1 diabetes (T1D)…
- Trial name
- NCT04878120
- Testing
- Standard HCL System, HCL System with Smart Bolus Calculator
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Virginia
Type 2 Diabetes Mellitus
Safety and Efficacy of Sitagliptin Compared With Glimepiride in Elderly Participants With Type 2 Diabetes Mellitus (MK-0431-251)
The primary objectives of this study are to determine if sitagliptin treatment is not inferior to that of glimepiride as measured by the change in baseline hemoglobin A1C (HbA1C) after 30 weeks of treatment, and if sitagliptin…
- Trial name
- NCT01189890
- Testing
- sitagliptin phosphate, Glimepiride
- Volunteers
- 480 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 1 Diabetes, Type 2 Diabetes
ACCESS: AI for pediatriC diabetiC Eye examS Study
The purpose of this study is to determine if providing in clinic point-of-care autonomous AI diabetic retinopathy exams improves screening rates compared to standard of care referral to an eye care provider, in a randomized…
- Trial name
- ACCESS (NCT05131451)
- Testing
- Point of Care Autonomous AI diabetic retinopathy exam
- Where
- United States
- Volunteers
- 164 people
- Sponsor
- Johns Hopkins University
Type 1 Diabetes Mellitus
PRISM for Adolescents With Type 1 Diabetes
It is well-known that adolescents with type 1 diabetes are at high risk for elevated diabetes-specific distress and poor glycemic control.
- Trial name
- NCT03847194
- Testing
- Promoting Resilience in Stress Management (PRISM)
- Where
- 2 sites in United States
- Volunteers
- 172 people
- Sponsor
- Seattle Children's Hospital
Diabetes Mellitus, Type 1
ACCU-CHEK Connect Personal Diabetes Management Study (PDM CONNECT)
This post-market, interventional, prospective, single arm, the United States (US) based multi-center study will assess the change in treatment satisfaction of participants who utilize the ACCU-CHEK Connect Diabetes Management…
- Trial name
- NCT02600845
- Testing
- ACCU-CHEK
- Where
- 11 sites in United States
- Volunteers
- 122 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus
Integration of Continuous Glucose Monitoring Into a BiHormonal Closed-Loop Artificial Pancreas
The investigators hypothesize that our closed-loop glucose-control system can provide BG control in subjects with type 1 diabetes using the estimated BG signal from a CGM as the input signal to the controller.
- Trial name
- CL2 (NCT01161862)
- Testing
- Bi-hormonal (insulin and glucagon) artificial pancreas
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Boston University Charles River Campus
Diabetes Mellitus, Type 1 Diabetes
Medtronic Treat to Range (TTR) Closed-Loop Control
The purpose of this study is to evaluate a treat-to-range automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes.
- Conditions
- Diabetes Mellitus, Type 1 Diabetes, Metabolic and Nutritional Disorders
- Trial name
- NCT01490151
- Testing
- TTR controller (Medtronic)
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Stanford University
Type 2 Diabetes Mellitus
A Phase 1 Study of Ertugliflozin in Healthy Male Participants (MK-8835-020)
This study will evaluate the absolute oral bioavailability (F) and fraction absorbed (Fa) of ertugliflozin following oral administration of unlabeled ertugliflozin (MK-8835) and intravenous (IV) and oral administration of…
- Trial name
- NCT02411929
- Testing
- Unlabeled ertugliflozin for oral use, 14^C-labeled ertugliflozin for IV use, 14^C-labeled ertugliflozin for oral use
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 1
The Bio-Inspired Artificial Pancreas for the Home
The purpose of the study is to evaluate the safety and effectiveness of a closed-loop insulin delivery system (also known as an artificial pancreas) which is made up of three components that communicate with each other: 1.
- Trial name
- BiAP@home (NCT03740698)
- Testing
- BiAP, ABC4D
- Where
- United Kingdom
- Volunteers
- 8 people
- Sponsor
- Imperial College London
Diabetes Mellitus, Type 2
Efficacy and Safety of BI 1356 BS (Linagliptin) in Combination With Metformin in Patients With type2 Diabetes
The objective of the study is to test the efficacy, safety and tolerability of several doses of BI 1356 BS (1, 5, or 10 mg taken once daily) compared to placebo given for 12 weeks together with metformin in patients with type 2…
- Trial name
- NCT00309608
- Testing
- Linagliptin, Glimepiride
- Where
- 48 sites in France, Germany and 4 more
- Volunteers
- 333 people
- Sponsor
- Boehringer Ingelheim
Type 1 Diabetes, Hypoglycemia
Glycemic Effects of Morning Only, Evening Only or Twice Daily Insulin Glargine in Patients With Type 1 Diabetes
This research is a prospective, randomized, cross-over study that is being done to compare the effect of morning only, evening only and twice daily insulin glargine (Lantus®) on hypoglycemia (blood glucose level <70 mg/dL) as…
- Trial name
- NCT00869414
- Testing
- Evening only administration of insulin glargine, Morning only administration of insulin glargine, split dose insulin glargine
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Johns Hopkins University
Type 1 Diabetes, Hypoglycemia
Islet Allotransplantation With Steroid Free Immunosuppression
The restoration of endogenous insulin secretion carries significant hopes for shifting the paradigm of life long exogenous insulin therapy in selected groups of patients with type 1 diabetes(T1D).
- Conditions
- Type 1 Diabetes, Hypoglycemia, Metabolic Diseases
- Trial name
- NCT00446264
- Testing
- islet transplantation, daclizumab - sirolimus - tacrolimus
- Where
- France
- Volunteers
- 14 people
- Sponsor
- University Hospital, Lille
Diabetes Mellitus, Type 1
Tailored Diabetes Self-Management Resources
Children with type 1 diabetes face complex self-management regimens which make adherence challenging and ultimately result in poor blood sugar control.
- Trial name
- NCT02024750
- Testing
- Tailored Resources
- Where
- 2 sites in United States
- Volunteers
- 214 people
- Sponsor
- University of Wisconsin, Madison
Diabetes Mellitus, Type 2 Diabetes Mellitus
Financial Incentives Telephone Education and Skills Trial in African Americans With Diabetes (FITEST)
The aim of this study is to test the efficacy of financial incentives augmented telephone-delivered diabetes education and skills training intervention in improving HbA1c levels in African Americans (AA) with type 2 diabetes…
- Conditions
- Diabetes Mellitus, Type 2 Diabetes Mellitus, Adult-Onset Diabetes Mellitus, Non-Insulin-Dependent Diabetes Mellitus
- Trial name
- FITEST (NCT02722499)
- Testing
- High Frequency Financial Incentive, Moderate Frequency Financial Incentive, Low Frequency Financial Incentive
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- State University of New York at Buffalo
New-onset Type 1 Diabetes
A Study to Assess Efficacy/Safety of Ladarixin in Type 1 Diabetes Patients With Preserved ß-cell Function at Baseline.
The objective of this clinical trial was to assess whether ladarixin treatment is effective to improve glycemic control in newly diagnosed Type 1 Diabetes (T1D) adult patients with preserved β-cell function.
- Trial name
- NCT04899271
- Testing
- Ladarixin
- Where
- 16 sites in United States, Belgium and 4 more
- Volunteers
- 25 people
- Sponsor
- Dompé Farmaceutici S.p.A
Diabetes, Diabetes Mellitus, Type 1
Comparison of NPH Insulin and Insulin Detemir in Children and Adolescents With Type 1 Diabetes
This trial is conducted in Europe. The aim of this research is to compare the efficacy and safety of treatment with NPH insulin and insulin detemir.
- Trial name
- NCT00435019
- Testing
- insulin detemir, insulin NPH, insulin aspart
- Where
- 43 sites in Bulgaria, Czechia and 9 more
- Volunteers
- 348 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes Mellitus
Propranolol in Treating Hypoglycemia Unawareness
Impaired awareness of hypoglycemia is common in type 1 diabetes (T1DM) patients. Impaired hypoglycemia awareness increases severe hypoglycemia risk by six-fold.
- Trial name
- NCT03161964
- Testing
- Propranolol 80 Mg Oral Capsule, Extended Release
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Anu Sharma
Hypoglycemia, Diabetes Mellitus, Type 1
Trial to Confirm the Clinical Efficacy and Safety of Dasiglucagon in the Treatment of Hypoglycemia in Subjects With T1DM
A randomized, double-blind, parallel-group trial to confirm the clinical efficacy and safety of dasiglucagon in the rescue treatment of hypoglycemia in subjects with type 1 diabetes mellitus (T1DM) compared to placebo
- Trial name
- NCT03688711
- Testing
- Dasiglucagon
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- Zealand Pharma